Sensei Biotherapeutics' Upcoming Presentations at Leading Conferences
BOSTON — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) is gearing up for a notable presence at two key scientific conferences that promise to share groundbreaking developments in cancer therapeutics. The company specializes in innovative treatments designed specifically for cancer patients, showcasing their commitment to enhancing the outcomes in this serious area of healthcare.
Details of the Conferences
The first significant event is the PEGS Europe: Protein and Antibody Engineering Summit, taking place from November 5 to November 7. This summit will be hosted in Barcelona, and it provides a fantastic opportunity for experts in the field to engage and discuss advancements in antibody therapies.
Presentation at PEGS Europe
The title of Sensei's presentation will focus on Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody. Leading the charge, Dr. Edward van der Horst, the Chief Scientific Officer, will present in the Antibody-Based Cancer Therapies session scheduled for November 5 at 9:00 a.m. CET. This presentation aims to highlight how SNS-101 can selectively block VISTA, a known suppressor of T cell activation, specifically within low pH conditions typical of the tumor microenvironment.
Participation at SITC Annual Meeting
Beyond Barcelona, Sensei Biotherapeutics will also participate in the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. This meeting is slated for November 6-10 in Houston, Texas, and serves as a convergence point for innovative cancer treatment methodologies and therapeutic discussions.
Insights from the SITC Meeting
During this gathering, Dr. F. Donelson Smith, Senior Director of Biologics Discovery & Early Development at Sensei, will present findings on Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications. His presentation, which falls under the poster presentation category, is set for November 9 with two time slots: 12:15–1:45 p.m. and 7:00–8:30 p.m. CST. This deep dive into VISTA and its interaction patterns is expected to shed light on potential avenues for developing effective cancer therapies.
About Sensei Biotherapeutics and Its Mission
At the forefront of innovative cancer treatment, Sensei Biotherapeutics (NASDAQ: SNSE) is dedicated to advancing the field of next-generation therapeutics. Their proprietary platform, TMAb™ (Tumor Microenvironment Activated biologics), enables the creation of conditionally active therapies designed meticulously to inhibit immunosuppressive signals or amplify immunostimulatory signals within the tumor microenvironment.
Among Sensei's promising investigational candidates is SNS-101, which effectively targets VISTA within the tumor microenvironment, disrupting its suppressive influence over T cells. The company is also innovatively developing SNS-102, SNS-103, and SNS-201, each targeting different pathways and mechanisms to boost immune responses against tumors, showcasing a wide array of solutions to cancer treatment.
Engagement and Updates
For those interested in following Sensei Biotherapeutics' journey, details about their conferences and other exciting updates are available on their website. Potential investors and the public alike can stay connected with the company on X @SenseiBio, as well as on LinkedIn for further insights and updates.
Investor inquiries can be addressed to Michael Biega, Senior Director of Investor Relations, via email. Media inquiries can reach Joyce Allaire at LifeSci Advisors.
Frequently Asked Questions
What is Sensei Biotherapeutics known for?
Sensei Biotherapeutics is a clinical stage company focusing on the discovery and development of advanced therapeutics specifically targeted for cancer treatment.
Which conferences will Sensei Biotherapeutics be presenting at?
They will be presenting at PEGS Europe and the SITC 39th Annual Meeting, discussing their innovative research and developments in cancer therapeutics.
Who are the presenters for Sensei Biotherapeutics at these events?
Dr. Edward van der Horst will present at PEGS Europe, while Dr. F. Donelson Smith will showcase findings at the SITC Annual Meeting.
What is SNS-101?
SNS-101 is a conditionally active monoclonal antibody developed by Sensei Biotherapeutics aimed at blocking the VISTA checkpoint in the tumor microenvironment.
How can interested parties stay updated on Sensei Biotherapeutics?
Interested individuals can follow the company on social media platforms like X and LinkedIn, in addition to visiting their website for the latest information.
